Picard Medical, Inc. Common Stock (PMI)

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, today announced that it has filed a class action lawsuit against Defendants Picard Medical Inc., Patrick NJ Schnegelsberg, Matt Schuster, Yuncai “Richard” Fang, Chris Hsieh, Westpark Capital, Inc., Sentinel Brokers Company, Inc., R.F. Lafferty & Co. Inc., American Trust Investments, and MaloneBailey, LLP (collectively, the “Defendants”). The action, which was filed in the U.S. District Court for the Northern District of California and captioned Louie v. Picard Medical, Inc. et al., Case No. 5:26-cv-01024, asserts claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased Picard Medical Securities (“PMI”) between September 2, 2025, and October 31, 2025, inclusive (the “Class Period”), and who were damaged thereby. The lead plaintiff deadline in this action is April 3, 2026.

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Picard Medical, Inc. (NYSE American: PMI) between September 2, 2025 and October 31, 2025, inclusive (the “Class Period”). Picard claims to design, manufacture, and sell medical device products.

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Picard Medical, Inc. (NYSE: PMI) securities between September 2, 2025 and October 31, 2025. Picard Medical claims to engage in designing, manufacturing, production, supply, marketing, and sale of medical device products.